Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome

Leuk Res. 2011 Jan;35(1):136. doi: 10.1016/j.leukres.2010.08.004. Epub 2010 Sep 15.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Comment

MeSH terms

  • Adult
  • Aged
  • Dose-Response Relationship, Drug
  • Humans
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / genetics
  • Male
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / administration & dosage
  • Pyrimidines / therapeutic use*
  • Remission Induction*

Substances

  • Protein Kinase Inhibitors
  • Pyrimidines
  • Protein-Tyrosine Kinases
  • nilotinib